arrow
H

Howard M. Saal

University of Alabama System
H指数:47
被引数:8,171

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)

伦伐替尼(L)和索拉非尼(S)在晚期或不可切除的肝细胞癌(uHCC)患者(pts)中的应用:一项国际、多中心、IV期研究(STELLAR)。

2024-09-010
PRE
Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada

接受仑伐替尼单药治疗的放射性碘难治性分化型甲状腺癌(RAI-R DTC)患者:欧洲和加拿大的真实世界治疗模式与临床结局

2024-09-010
PRE
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
2024-01-0119
PRE
Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study

软骨发育不全儿童的生长参数: 一项为期7年的前瞻性多国观察性研究

2022-12-017
PRE
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
2021-12-0152
OAAI
Best Practices for the Diagnosis and Evaluation of Infants With Robin Sequence A Clinical Consensus Report
2016-09-01147
OAAI
The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant
2015-08-26100
OAAI
Mutations in the Endothelin Receptor Type A Cause Mandibulofacial Dysostosis with Alopecia

A型内皮素受体的突变导致下颌面部发育不良伴脱发

2015-04-0140
OAAI